CorAlert is developing a noninvasive device for the early detection and monitoring of heart failure in real time. Suitable for both inpatient and outpatient environments, the device accurately estimates left ventricular end-diastolic pressure (LVEDP) by analyzing central aortic pressure derived from measurements of pressure at the brachial artery and timing measurements based on heartbeat sounds. The CorAlert device provides a comprehensive hemodynamic picture that includes the rate of pressure increase in the aorta during ejection (dP/dt) and an index correlated to systemic vascular resistance (SVR). The comprehensive hemodynamic profile supplied by the device enables the physician to accurately determine each patients precise condition and type of dysfunction. The companys solution was validated in 10 patients in a clinical trial conducted at Ziv Medical Center in Israel using CorAlerts alpha model. CorAlert has completed production of its beta model, which has commenced a clinical trial in Israel.